UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 93-0797222 (State or other ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q2 2022 Earnings Conference Call August 2, 2022 4:30 PM ET Company Participants Mary Jenkins - Senior Manager of Investor Relations Doug Ingram - President & Chief Executive Officer Louise Rodino-Klapac - Executive Vice President, Chief Scientific Officer and Head of R&D Dallan Murray - Senior Vice President & Chief Customer Officer Ian Estepan - Executive Vice President & Chief Financial Officer Gilmore O'Neill - Chief Medical Officer & Executive Vice President Conf ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 For the transition period from to Commission file number 001-14895 SAREPTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (I.R.S. Employer Identification No.) Regi ...

| --- | --- | --- | --- | |-----------------------------------------------------------------|-------|--------------------------------------------------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | SRP-9001: New Clinical Data and Integrated Analysis | | | | | | | | | | DOUG INGRAM President and Chief Executive Officer | | | | | LOUISE RODINO-KLAPAC, PH.D. | | | | | Executive Vice President, Head of R&D, Chief Scientific Officer | | | | | July 6, 2022 8:30 a.m. ET | | | | | | | ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Mary Jenkins - Senior Manager of Investor Relations Dallan Murray - Senior Vice President & Chief Customer Officer Doug Ingram - President & Chief Executive Officer Ian Estepan - Executive Vice President & Chief Financial Officer Louise Rodino-Klapac - Executive Vice President, Chief Scientific Officer and Head of R&D Conference Call Participants Colin Bristow - UBS Brian Abrahams - RBC Capi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 93-0797222 (State or other juri ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q4 2021 Earnings Conference Call March 1, 2022 4:30 PM ET Company Participants Mary Jenkins - Senior Manager of Investor Relations Doug Ingram - President & Chief Executive Officer Ian Estepan - Executive Vice President & Chief Financial Officer Dallan Murray - Senior Vice President & Chief Commercial Officer Gilmore O'Neill - Executive Vice President of R&D & Chief Medical Officer Louise Rodino-Klapac - Executive Vice President & Chief Scientific Officer Conference ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number : 001-14895 Sarepta Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 93-0797222 (State or other jurisdi ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q3 2021 Earnings Conference Call November 3, 2021 4:30 PM ET Company Participants Mary Jenkins - Senior Manager of Investor Relations Doug Ingram - President & Chief Executive Officer Ian Estepan - Executive Vice President & Chief Financial Officer Dallan Murray - Senior Vice President & Chief Commercial Officer Gilmore O'Neill - Executive Vice President of R&D & Chief Medical Officer Louise Rodino-Klapac - Executive Vice President & Chief Scientific Officer Conferen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 93-0797222 (State or other ...